Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-07-23 02:06 CEST (UTC+2h)

steady state in WinNonlin (example) [Software]

posted by Helmut Homepage - Vienna, Austria, 2007-04-05 17:16  - Posting: # 634
Views: 7,903


» Thanks for your instructions. However, I have two problems:
» 1. The version 5.01 of WinNonLin that I have do not have "Linear" function in the PK/PD/NCA Wizard.

Just looked it up in the release notes, linear models were introducted in v5.1 (23 Oct, 2006). If you have a valid license (which I assume), you may update at no costs.

» 2. The approach I would like to use for the assessment of steady state is repeated measures ANOVA of log concentrations instead of linear regression you are describing, since I am comparing the pre-dose concentrations in several subjects on three consecutive days.

» If I have one dependent variable (concentration) and subject as a random effect (??), and day as a fixed effect (???), how can I use Lin Mix to do the calculations.

OK, ANOVA is not included in WinNonlin; you will have to fight through a Linear Mixed Effects Model (which is always a little bit tricky). One hint: all effects are fixed!
Since I haven't done this myself yet, maybe another member of the forum can fill in the gap?
...or ask Pharsight's support - and be patient!

I know some colleagues are using repeated measures ANOVA; I never could understand why.
The outcome is always a yes/no result.
What if you get a significant result - would you really throw away the entire study?
If you are testing individual subjects, you have the option - providing you have stated such a procedure in the protocol - to exclude only these subjects from the evaluation since they did not reach steady state.

» In the linear regression while assessing the slope, should it be 95% or 90% CI?

95% since p = 1-alpha, where alpha=0.05. This is only a convention.

In BE we are only using a 90% CI, because in patients BA of the test can either be lower (5%) or higher (5%) then BA of the reference.
Therefore the individual patient's risk is kept at 5%.

Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,547 posts in 3,941 threads, 1,190 registered users;
online 11 (0 registered, 11 guests [including 11 identified bots]).

[The] impatience with ambiguity can be criticized in the phrase:
absence of evidence is not evidence of absence.    Carl Sagan

BEBAC Ing. Helmut Schütz